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Abstract
Background: The level of loss of heterozygosity (LOH) that reduces a gene dose and exerts a cell-adverse effect is
known to be a parameter for the genetic staging of gastric cancers. This study investigated if the cell-adverse
effect induced with the gene reduction was a rate-limiting factor for the LOH events in two distinct histologic
types of gastric cancers, the diffuse- and intestinal-types.
Methods: The pathologic specimens obtained from 145 gastric cancer patients were examined for the level of
LOH using 40 microsatellite markers on eight cancer-associated chromosomes (3p, 4p, 5q, 8p, 9p, 13q, 17p and
18q).
Results: Most of the cancer-associated chromosomes were found to belong to the gene-poor chromosomes and
to contain a few stomach-specific genes that were highly expressed. A baseline-level LOH involving one or no
chromosome was frequent in diffuse-type gastric cancers. The chromosome 17 containing a relatively high density
of genes was commonly lost in intestinal-type cancers but not in diffuse-type cancers. A high-level LOH involving
four or more chromosomes tended to be frequent in the gastric cancers with intestinal and mixed differentiation.
Disease relapse was common for gastric cancers with high-level LOH through both the hematogenous (38%)
and non-hematogenous (36%) routes, and for the baseline-level LOH cases through the non-hematogenous
route (67%).
Conclusions: The cell-adverse effect of gene reduction is more tolerated in intestinal-type gastric cancers than in
diffuse-type cancers, and the loss of high-dose genes is associated with hematogenous metastasis.
Background
Gastric cancers undergo hypermutations in simple
repeat sequences and imbalanced chromosomal losses,
and these genetic alterations are detected as a microsa-
tellite instability (MSI) and loss of heterozygosity (LOH),
respectively, by using highly polymorphic microsatellite
markers [1-4]. The pathobiological behavior and prog-
nosis of gastric cancers have been associated with the
level of LOH and the presence of MSI [3-6]. The depth
of invasion and lymph node metastasis are considerably
advanced in the cases of small-sized cancers with high-
level LOH, and these histologic parameters tends to be
linearly related with the cancer size for the low-level
LOH cases [7]. Because a single microsatellite genotype
is similarly detected in the entire surgical tissue as well
as the endoscopic biopsy sample [3,7], it is possible to
predict the probability of disease relapse and to decide
the appropriate resection procedure based on the micro-
satellite analysis of a pretreatment biopsy tissue.
The two-hits hypothesis has proposed that chromoso-
mal loss and point mutation result in the biallelic inacti-
vation of tumor suppressor genes [8]. Chromosomal
losses that exert a deleterious effect on cell growth are
much less tolerated than chromosomal gains, and the
two genetic hits providing a growth advantage could
protect cancer progenitor cells from lethal LOH events
[9,10]. Additionally, previous studies have proposed that
the methylated gene-control regions are decreasingly
methylated in a LOH-level-dependent manner in gastric
cancers [11,12] via a dosage compensation mechanism
that sustains a gene or transcription dose during sub-
sequent cell cycles [9]. With respect to the dosage
compensation mechanism, chromosomal gain and
* Correspondence: rhyumung@catholic.ac.kr
† Contributed equally
1Department of Microbiology, College of Medicine, The Catholic University
of Korea, Seoul, Korea
Full list of author information is available at the end of the article
Hong et al. BMC Gastroenterology 2010, 10:138
http://www.biomedcentral.com/1471-230X/10/138
© 2010 Hong et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.LOH-associated demethylation may result from dose-
compensatory genetic and epigenetic responses to a
reduction in the chromosomal dose [11-14]. Therefore,
the LOH events combined with a cell-adverse effect and
a dose-compensatory response in addition to tumor sup-
pressor gene inactivation are likely to determine the
pathobiological behavior of cancer progenitor cells.
Gastric cancers have been categorized into two distinct
histologic types, that is, the diffuse- and intestinal-types
[15,16]. Diffuse-type cancers are common in young-aged
patients who lack a precancerous lesion, whereas intest-
inal-type cancers are common in old-aged patients asso-
ciated with the precancerous intestinal metaplasia that
resemble intestinal glands [17]. Assuming that the mar-
row-derived stem cells are adapting to the stomach tis-
sue-environment [18], the newly-fixed stem cells, which
are potentially non-cohesive and invasive in young indivi-
duals, develop into diffuse-type cancer. Intestinal-type
cancers are frequent among the old-aged patients who
have the long-term adaptation of newly-fixed stem cells
to the gastric tissue environment. In this regard, a given
LOH event may affect distinct doses of transcription
between diffuse- and intestinal-type gastric cancers that
establish distinct gene expression patterns.
In this study, correlations were made between the
LOH events and pathobiological behavior of gastric can-
cers in terms of the cell-adverse effects of gene reduc-
tion. The eight cancer-associated chromosomes we
examined had a low density of genes and no stomach-
specific genes, which could result in a mild cell-adverse
effect of LOH. The LOH events were frequent in intest-
inal-type gastric cancers, in which the loss of a chromo-
some would affect a low dose of transcription and exert
a mild cell-adverse effect.
Methods
Selection of cases
One hundred and forty-five patients with gastric cancer
who underwent a curative surgical resection between
February 1996 and June 2003 were enrolled in this study.
The clinicopathologic and radiologic information was
obtained by reviewing the detailed records of the
patients. One hundred and sixteen cases were previously
analyzed by multifocal genetic examination of the hetero-
geneous tumor sites [3]. The remaining 29 patients were
examined using a single tissue block of each tumor.
The microscopic slides were reviewed and then a
tumor site that was representative of the histologic fea-
ture was chosen. The histologic type of gastric cancer
was defined as intestinal (glandular, cohesive or solid),
diffuse, and mixed according to the Lauren classification
[15,16] and the degree of differentiation was graded
according to the WHO classification. The tumor loca-
tions considered were the cardia, body, and antrum. The
clinicopathologic tumor stage was determined according
to the Tumor-Node-Metastasis (TNM) criteria [19].
Most gastric cancer patients (140 of 145, 97%) had
undergone R0 gastrectomy and D2 or more extended
lymphadenectomy. An overall mean of 28.6 (median: 33)
lymph nodes were removed along with the specimen.
None of the patients received pre-operative chemother-
apy and radiation therapy.
Follow-up data on recurrence and survival
A combination therapy of intravenous mitomycin, fluor-
ouracil, and cytarabine (MFC) followed by oral fluoroura-
cil was administered as a standard postoperative adjuvant
treatment according to the physician’s judgment on the
overall prognosis of each case. During the follow-up
period, a physical examination, laboratory tests, chest
radiography, abdominal ultrasonography or computed
tomography, and gastrofiberscopy were carried out every
3 or 6 months and disease relapse was histologically con-
firmed, if possible. When more than one recurrence site
w a sd e t e c t e da tt h ef i r s tt i m e of failure, the individual
recurrences were counted separately. The recurrence site
was categorized into hematogenous metastasis involving
the lung, liver, or other distant organs, and non-hemato-
genous metastasis that included nodal involvement and
peritoneal dissemination. Gastric remnant cancers were
excluded from the recurrence pattern analysis.
The overall survival time was calculated from the date
of surgical resection until either the day of the last fol-
low-up contact or cancer-related death. The data on
patients who died from other causes was censored at
the time of death. Statistical analysis was performed in
April 2007. The mean follow-up period of all the surviv-
ing patients was 40 months (range: 5 to 96 months) and
was completed by 98% of the enrolled patients. During
the survival analysis, 50 patients had died as a result of
their cancers and 12 patients had died of other causes.
Tissue microdissection and DNA amplification
Five serial 7 μm-thick sections from each formalin-fixed
paraffin-embedded tissue sample were deparaffinized
and briefly stained with hematoxylin and eosin. A single
tumor-cell-rich focus was chosen by microscopic exami-
nation and a tumor area ranging from 5 mm to 7 mm
in diameter was manually dissected under a stereomi-
croscope (magnification, × 40) using a surgical scalpel.
The microdissected tissue pieces were microscopically
examined if the tumor cell content was > 70%, which
had been confirmed to reflect a difference in the genetic
content between the normal and tumor tissues [3,7].
Approximately 1,000 microdissected tumor cells were
incubated in 20 μL of DNA extraction buffer (0.5%
Tween-20, 1 mM EDTA pH 8.0, 50 mM Tris pH 8.0,
0.5 mg/mL proteinase K) at 37°C for 24 hr. Formalin-
Hong et al. BMC Gastroenterology 2010, 10:138
http://www.biomedcentral.com/1471-230X/10/138
Page 2 of 14fixed paraffin-embedded tissue DNA tends to be poorly
amplified by PCR in older specimens. Most DNAs were
extracted within five years after the preparation of the
pathological specimens, which ensures the DNA’sq u a l -
ity for PCR. The amount of DNA, with varying qualities,
of the tissue lysate was determined based on the PCR
band intensity with 5-10 ng/μLo ft h eD N A ,w h i c hw a s
amplified using a microsatellite primer set, D19S226
(forward: 5’ - CCA GCA GAT TTT GGT GTT GTC
TA - 3’;r e v e r s e :5 ’ - ACA GAG CCA GAG CCA GTA
GGA GT - 3’; amplicon size: 164 bp). The PCR amplifi-
cation was performed under a hot-start condition with
using a radioisotope (a-
32P dCTP, PerkinElmer, Boston,
MA, USA) as described previously [3,7]. Briefly, a total
of 10 μL PCR mixture underwent 32 cycles of a serial
amplification step that consisted of 94°C for 50 sec, a
primer-specific annealing temperature for 50 sec, and
72°C for 1 min. The radioisotope-labeled microsatellite
sequences were separated on a 6% polyacrylamide gel
that contained 7 M urea and they were visualized by
repeated exposures of each autoradiograph and using a
radioluminograph scanner (BAS 2500, Fuji Photo Film
Co. Ltd., Kanakawa, Japan).
Analysis of microsatellite alleles
The guidelines for scoring the status of LOH and MSI
have been detailed in previous studies that used the
same panel of microsatellite markers [7]. As a reference
type of the microsatellite alleles, we retrieved the dinu-
cleotide repeat markers that ranged from 88 bp to
247 bp in amplicon size and that had a heterozygous
frequency >50%. The highly polymorphic microsatellite
markers on 8 cancer-associated chromosomes (3p, 4p,
5q, 8p, 9p, 13q, 17p and 18q), which frequently suffered
from LOH in gastric cancer [3,7,20], were used to
increase the number of heterozygous alleles on each
arm (Figure 1A). The five microsatellite markers on
each chromosomal arm showed the clear PCR bands of
the heterozygous alleles and spanned the entire length
of the eight chromosomes [3,5]. To ensure the chromo-
somal reduction, the chromosomal loss was assigned
when the LOH event involved more than two microsa-
tellite markers on one chromosomal arm [13]. Forty
pairs of microsatellite primers were mixed in a total of
22 reaction tubes and each of which contained one
(4 mixtures) or two (18 mixtures) primer sets that
spanned different-sized amplicons at the same annealing
temperatures. The resultant unequivocal microsatellite
bands indicated the high specificity of the multiplex
PCR condition, which was useful for small amounts of
microdissected pathologic tissues.
Based on the same classification of the microsatellite gen-
otypes that was applied in the previous study (Figure 1B)
[7], the allelic profiles of the 40 microsatellite markers were
analyzed for MSI at the homozygous markers that
showed a few shadow or stutter bands in a pair of nor-
mal and tumor DNAs. Because MSI obscures the het-
erozygous allelic status, the allelic profiles of the 40
microsatellite sequences were initially analyzed for MSI
at the homozygous markers. The LOH status was
determined based on the allelic loss in the heterozy-
gous marker (Figure 1B). The extent of chromosomal
losses in each case was scored according to the num-
ber of constitutional chromosomal losses involving
more than one microsatellite allele.
Analysis of in-silico data for the gene density and
transcription of individual chromosomes
A total of 17,723 reference genes identified in a public
database (http://genome.ucsc.edu/, March 2006 assem-
bly) [21] were analyzed to calculate the number of genes
per 1-Mb nucleotides segment. Serial analysis of gene
expression (SAGE) data of normal gastric mucosa was
obtained from a public database (http://www.ncbi.nlm.
nih.gov/geo/, “SAGE_Stomach_normal_B_antrum”). The
transcriptional activity of individual genes was calculated
by combining the reference gene map and the expressed
gene tags. Based on a comparison of the microarray and
SAGE data evaluating the gene expression profiles, the
number of transcripts counted in the SAGE data was
found to accurately estimate a great difference in the
gene activity between the stomach-specific genes and
housekeeping genes [21].
Statistical analysis
Fisher’s exact test and c
2 tests were used to compare the
clinicopathologic features with the microsatellite geno-
type of the gastric cancers. Probability curves were cal-
culated according to the Kaplan-Meier method and
compared using the log-rank test. Multivariate analysis
was performed by the Cox’s proportional hazards
method with using stepwise procedures. Probability
values were two-tailed, with a P value less than 0.05
being regarded as statistically significant. The statistical
software package SPSS 11.0 (SPSS Inc., Chicago, IL,
USA) was used for data analysis.
Results
Analysis of the LOH events in gastric cancers
Most of the gastric cancers (116 out of 145 cases) were
examined in a previous multifocal analysis on the het-
erogeneous tumor sites from a given gastric cancer [3].
Ninety five percent of the gastric cancers examined
were found to have either a similar level of LOH or MSI
commonly shared by heterogeneous tumor sites and
then each gastric cancer was categorized into a single
microsatellite genotype, and not a mixed genotype. The
microsatellite genotypes of the 27 additional cases were
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Page 3 of 14Figure 1 The PCR-based microsatellite analysis (A) and the genetic classification of gastric cancers (B). Representative autoradiographs of
the samples that were examined by PCR-based microsatellite analysis (A) and the genetic classification of the intestinal-type and diffuse-type
gastric cancers based on loss of heterozygosity (LOH) and microsatellite instability (MSI) (B). (A) The left gel electrophoresis shows high-frequency
MSI at more than 40% of the 15 homozygous markers. The right gel electrophoresis shows high-level LOH involving chromosomes 3p, 4p, 5q,
9p, 13q, 17p and 18q. The normal (N) and corresponding tumor (T) DNAs are indicated above each allelic band. The asterisk indicates MSI and
LOH. The genomic DNA microdissected from formalin-embedded paraffin-fixed tissue was amplified and labeled by [a-32P]dCTP in the hot start
condition of multiplex PCR. A total of 80 microsatellite amplicons from each specimen were run simultaneously on two sequencing gels. (B)
Using a panel of 40 microsatellite markers on eight cancer-associated chromosomes, LOH was interpreted at the heterozygous markers if 40% or
less of the homozygous markers exhibited MSI. The extent of the chromosomal losses, as scored according to the number of LOH-positive
chromosomes, was divided into high-level (LOH-H) and low-level (LOH-L) losses for both the intestinal-and diffuse-types. In cases of diffuse type
gastric cancers, zero or one chromosomal loss was classified into the baseline-level (LOH-B).
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of MSI, which were detected in a single tissue piece
containing a representative histological component.
Each chromosomal loss was correlated with the clini-
copathologic parameters of the gastric cancers (Table 1).
Most chromosomal losses (4 p ,5 q ,9 p ,1 3 q ,1 7 pa n d
18q) were associated with late-onset disease (P <0 . 0 5 ) .
Two or more chromosomal losses were concurrently
related with the antral location (9p and 18q losses), the
intestinal-or mixed-type histology (5q, 17p and 18q
losses), and a poor survival (3p, 9p and 13q losses) (P <
0.05). The 17p loss was most frequent in the intestinal-
type cancers (67%). The 13q loss was most frequent in
the diffuse-type cancers (47%).
A large fraction (52%) of diffuse-type gastric cancers had
one or no chromosomal losses, which were classified into
a baseline-level LOH (LOH-B), because most of the intest-
inal-and mixed-type cancers (86%) had two or more chro-
mosomal losses (Figure 2) [7]. The high-level LOH cases
with four or more chromosomal losses were most frequent
in the mixed differentiation cases with both intestinal- and
diffuse-type gastric cancers (44%). Overall, 15 LOH-B
(10%), 65 LOH-L (45%), 50 LOH-H (35%), and 15 MSI
(10%) cases were identified in the 145 surgical specimens.
Table 1 Relationships of the clinicopathologic characteristics and single chromosomal loss
Characteristics 3p loss 4p loss 5q loss 8p loss 9p loss 13q loss 17p loss 18q loss
No. of patients 130 47 47 51 30 50 57 77 55
Age
Mean 60 61 63 63 63 64 63 63 63
± SD ± 12.60 ± 10.18 ± 10.49 ± 9.28 ± 10.24 ± 10.28 ± 10.43 ± 10.94 ± 11.20
P 0.290 0.029 0.014 0.102 0.003 0.030 < 0.0001 0.030
Sex
Male 86 37 34 36 18 37 42 52 36
Female 44 10 13 15 12 13 15 25 19
P 0.033 0.335 0.450 0.510 0.182 0.136 0.710 1.000
Tumor location
Cardia 13 43512 5 8 3
Body 48 16 16 13 10 14 16 24 16
Antrum 69 27 28 33 19 34 36 45 36
P 0.743 0.424 0.078 0.267 0.018 0.119 0.253 0.043
Histologic type
Intestinal 54 19 19 23 13 22 20 36 27
Diffuse 32 996581 51 1 7
Mixed 44 19 19 22 12 20 22 30 21
P 0.395 0.395 0.018 0.480 0.176 0.404 0.004 0.026
Tumor size
Mean 5.3 5.8 5.1 4.9 5.1 4.9 5.7 5.2 5.5
± SD ± 3.01 ± 2.86 ± 2.64 ± 2.29 ± 2.42 ± 2.73 ± 3.02 ± 2.86 ± 3.13
P 0.129 0.631 0.131 0.705 0.181 0.179 0.564 0.483
Stage
I & II 64 20 21 20 14 22 21 36 24
I I I & I V 6 62 72 63 11 62 8 3 6 4 1 3 1
P 0.277 0.469 0.075 0.836 0.372 0.014 0.593 0.292
Recurrence
Peritoneal 24 10 9 8 5 10 12 16 11
Lymph node 10 43325 4 6 3
Hematogenous 22 13 11 14 8 11 14 15 10
Total 56 27 23 25 15 26 30 37 24
P 0.422 0.507 0.070 0.428 0.826 0.415 0.899 0.663
Vital status 119 42 41 47 29 44 51 68 48
Alive 70 19 21 26 16 20 24 36 27
Dead 49 23 20 21 13 24 27 32 21
P 0.021 0.152 0.330 0.402 0.019 0.019 0.094 0.389
P values less than 0.05 are indicated in boldface print.
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genes on cancer-associated chromosomes
The density of genes per 1-Mb segment, the top 100
active genes that were highly expressed in the stomach,
and the frequency of the LOH genotypes detected in
gastric cancers were analyzed on each chromosome
(Table 2). In comparison of the eight cancer-associated
chromosomes we examined and the remaining 14 chro-
mosomes, the density of genes (4.8 genes versus 6.9
genes per 1-Mb segment) and the average number of the
highly expressed genes (3.3 genes versus 5.3 genes) were
lower in the cancer-associated chromosomes than in the
other chromosomes. The mean number of transcripts
estimated in each highly expressed gene was also low in
the cancer-associated chromosomes (54 versus 69 tran-
scripts per each gene). The individual autosomes were
grouped in the order of gene densities. The chromo-
s o m e s2 ,3 ,4 ,5 ,8 ,1 3a n d1 8w e r ec a t e g o r i z e di n t ot h e
low-gene-density group of less than five genes per 1 Mb
segment. The chromosomes 11, 16, 17, 19, 20 and 22 had
ah i g hd e n s i t yo fg e n e so fm o r et h a ne i g h tg e n e sp e r1
Mb segment. Consequently, of the eight cancer-asso-
ciated genes that were examined, six (chromosomes 3, 4,
5, 8, 13 and 18) belonged to the gene-poor chromosomes,
and the remaining two genes belonged to the intermedi-
ate-(the chromosome 9) and high-(the chromosome 17)
gene-density groups. The chromosomes 17 and 13 con-
tained high and low densities of genes (13.4 and 2.7
genes per 1-Mb segment), respectively. Chromosome 17
showed a high frequency of LOH in the LOH-L (49%)
but not in the LOH-B cases (13%). The frequency
of chromosome 13 loss was similar in the LOH-L (25%)
and LOH-B cases (27%).
Relationships between the clinicopathologic features and
the microsatellite genotypes
The 145 gastric cancers were analyzed for the relation-
ships between the level of LOH and the clinicopathologic
features (Table 3). Both the LOH-H and LOH-B gastric
cancers were commonly associated with high-risk pheno-
t y p e ss u c ha sl y m p h a t i ci n v a s i o n( P = 0.006), venous
invasion (P = 0.005), advanced stages (P < 0.0001), recur-
rence (P = 0.023) and a poor survival rate (P < 0.0001),
whereas the LOH-L and MSI gastric cancers were corre-
lated with well and moderate differentiation (P = 0.033)
and an early tumor stage (P < 0.0001). The two genotypes
related with high-risk-phenotype were dissimilar accord-
ing to the anatomical site of occurrence and the pattern
of recurrence. The LOH-H cases frequently occurred in
the antral portion (70%) and they recurred through
hematogenous spreading to the liver, lung and other dis-
tant organs (38%), as well as non-hematogenous metasta-
sis such as peritoneal seeding and nodal involvement
(36%). Most of the LOH-B cases were present in the car-
diac and body portion (94%) and they relapsed in the
peritoneal cavity (67%), rather than in distant organs
(13%). The onset age of the LOH-B (45 years) and LOH-
H (65 years) cases was significantly different (P < 0.0001).
Figure 2 Relationships between the histologic type and no. of chromosomal losses in the gastric cancers. The histologic type of gastric
cancer was defined as the diffuse- (n = 32, closed box), intestinal- (n = 54, gray box), and mixed-types (n = 44, open box), according to Lauren
classification.
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correlated with late-onset disease (67 vs. 60 years, P =
0.038), female patients (73% vs. 34%, P = 0.008), intestinal-
and mixed-type cancers (100% vs. 75%, P = 0.016) and an
antral location (87% vs.5 1 % ,P = 0.037), as compared with
the LOH-L cases (Table 3). Favorable tumor behaviors
such as an expanding and mixed growth pattern (100% vs.
57%), no venous invasion (100% vs. 83%) and good survival
(91% vs. 87%) were more closely associated with the MSI
genotype than with the LOH-L genotype.
Progression and recurrence of the microsatellite
genotypes in relation to tumor size
The gastric cancers were analyzed for the progression
(Figure 3A) and recurrence patterns (Figure 3B) of the
microsatellite genotypes in relation to the tumor size.
Small gastric cancers ≤ 2 cm in diameter with LOH-H
(5 cases) and LOH-B (3 cases) often developed extraserosal
invasion (two LOH-H), nodal metastasis (one LOH-B and
two LOH-H), hematogenous recurrence (two LOH-H) and
peritoneal seeding (one LOH-B). All the small gastric can-
cers ≤ 2 cm in diameter with LOH-L (9 cases) and MSI (1
case) were free of extraserosal invasion, lymph node metas-
tasis and disease relapse. The LOH-L (21 cases) and MSI
(3 cases) gastric cancers ≤ 3c mi nd i a m e t e rs h o w e dn o
recurrence. Extraserosal invasion (LOH-L, 20 cases, 31%;
MSI, 6 cases, 40%) and lymph node metastasis (LOH-L, 22
cases, 34%; MSI, 4 cases, 27%) were frequently detected in
the large-sized LOH-L and MSI gastric cancers ≥ 5c mi n
diameter.
Prognostic implication of the three levels of chromosomal
losses and MSI
The LOH-H and diffuse-type LOH-B genotypes were
significantly associated with poor clinicopathological fea-
tures when compared with LOH-L and MSI cases
Table 2 The gene density, highly expressed genes, and LOH level on individual chromosomes estimated in stomach
cancerous and noncancerous tissues
No. of genes per a 1-Mb segment* Top 100 highly expressed genes
(No. of transcripts per gene)*
Level of LOH (%)
§
Baseline
(n = 15)
Low
(n = 65)
High
(n = 50)
Cancer-associated chromosomes
3 4.9 3 (76) 1 (7) 18 (28) 28 (56)
4 3.6 5 (53) 2 (13) 12 (18) 33 (66)
5 4.4 4 (44) 0 (0) 14 (22) 37 (74)
8 4.1 3 (32) 0 (0) 9 (14) 21 (42)
9 5.2 4 (60) 1 (7) 15 (23) 34 (68)
13 2.7 2 (121) 4 (27) 16 (25) 37 (74)
17 13.4 5 (42) 2 (13) 32 (49) 43 (86)
18 3.2 0 (0) 1 (7) 18 (28) 36 (72)
Mean values 4.8 3.3 (54)
Other chromosomes
1 7.7 8 (47)
2 4.7 9 (132)
6 5.8 7 (39)
7 5.2 6 (45)
10 5.0 2 (37)
11 8.9 9 (85)
12 7.3 10 (62)
14 5.3 6 (43)
15 5.3 2 (90)
16 8.6 3 (34)
19 19.8 8 (61)
20 8.3 2 (76)
21 5.1 1 (268)
22 8.4 1 (55)
Mean values 6.9 5.3 (69)
*The number of transcripts of 17,723 genes was analyzed using the previously published data [21].
§The details are described in the material and methods section.
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low-risk (MSI and LOH-L) and high-risk (LOH-H and
diffuse-type LOH-B) tumor according to the relation-
ships between the microsatellite genotypes and the
clinicopathologic features. The Kaplan-Meier survival
curves and the log-rank analysis demonstrated that the
low- and high-risk genotypes were significantly asso-
ciated with good and poor survivals in both stage II (P
= 0.0005) and stage III (P < 0.0001) gastric cancers
(Figure 4). The Cox’s proportional hazards models that
Table 3 Relationships between the microsatellite genotypes and the clinicopathologic features of gastric cancers
Characteristics High-risk genotypes Low-risk genotypes P value
(%) LOH-H (%)* LOH-B (%)* P value LOH-L (%)* MSI (%)* P value
No. of patient 145 50 15 65 15
Age (year) <0.0001 0.038 0.710
Mean 61 65 45 60 67
SD ± 12.5 ± 9.8 ± 12.7 ± 11.6 ± 9.8
Sex 0.118 0.008 0.393
Male 90 (62) 36 (72) 7 (47) 43 (66) 4 (27)
Female 55 (38) 14 (28) 8 (53) 22 (34) 11 (73)
Tumor size 0.247 0.502 0.394
Mean 5.34 5.3 6.34 5.0 5.6
SD ± 2.94 ± 2.62 ± 3.77 ± 3.10 ± 2.33
Differentiation 0.052 0.094 0.033
Well 11 (8) 3 (6) 8 (12)
Moderate 53 (36) 17 (34) 1 (7) 25 (39) 10 (67)
Poor 81 (56) 30 (60) 14 (93) 32 (49) 5 (33)
Tumor location <0.0001 0.037 0.791
Cardia 13 (9) 3 (6) 4 (27) 6 (9)
Body 50 (35) 12 (24) 10 (67) 26 (40) 2 (13)
Antrum 82 (56) 35 (70) 1 (6) 33 (51) 13 (87)
Lauren classification <0.0001 0.016 <0.0001
Intestinal 58 (40) 19 (38) 0 (0) 35 (54) 4 (27)
Diffuse 32 (22) 9 (18) 15 (100) 8 (12) 0 (0)
Mixed 55 (38) 22 (44) 0 (0) 22 (34) 11 (73)
Growth pattern 0.600 <0.0001 <0.0001
Expanding 20 (14) 1 (2) 1 (7) 9 (14) 9 (60)
Infiltrative 70 (48) 32 (64) 10 (67) 28 (43)
Mixed 55 (38) 17 (34) 4 (26) 28 (43) 6 (40)
Lymphatic invasion 1.000 0.771 0.006
No 44 (30) 9 (18) 3 (20) 34 (52) 5 (33)
Yes 101 (70) 41 (82) 12 (80) 31 (48) 10 (67)
Venous invasion 0.351 0.113 0.005
No 112(77) 35 (70) 8 (53) 54(83) 15 (100)
Yes 33 (23) 15 (30) 7 (47) 11 (17)
Tumor stage 0.757 0.763 <0.0001
Early 75 (52) 16 (32) 6 (40) 42 (65) 11 (73)
Advanced 70 (48) 34 (68) 9 (60) 23 (35) 4 (27)
Recurrence 0.035 0.517 0.023
Non-hematogenous 36 (62) 18 (36) 10 (67) 14 (22) 2 (13)
Hematogenous 22 (38) 19 (38) 2 (13) 3 (5)
Vital status 130 1.000 1.000 <0.0001
Alive 80 (61) 14 (32) 4 (27) 52 (87) 10 (91)
Dead 50 (39) 30 (68) 11 (73) 8 (13) 1 (9)
P values less than 0.05 are indicated in boldface print.
*The gastric cancers were categorized into high-level LOH (LOH-H), baseline-level LOH (LOH-B), low-level LOH (LOH-L) and microsatellite instability (MSI). The
details are described in the material and methods section.
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Page 8 of 14disclosed the microsatellite genotypes were the most
significant prognostic factor (Table 4): the hazards
ratios for cancer-related deaths in the patients with
high-risk genotype cancer vs.t h el o w - r i s kg e n o t y p e
cancer were 22.077 for stages II and III (model 1; 95%
confidence interval, 6.57-74.18; P < 0.0001). The high-
risk and low-risk genotypes were significant indepen-
dent factors of survival in stage II (model 3; 15.42, 95%
confidence interval, 1.71-139.5; P = 0.015) and stage III
(model 5; 19.69, 95% confidence interval, 4.38-88.53; P
< 0.0001). When removing the microsatellite genotypes
from the Cox’s models, the cancer stage, the tumor
size, the growth pattern and venous invasion were the
independent prognostic factors (models 2, 4 and 6).
Discussion
The cell-adverse effect of chromosomal loss is considered
principally as a rate-limiting factor for the occurrence of
LOH. For example, the postnatal survival for monosomy
22q11 (DiGeorge syndrome) [22,23] is a function of the
deletion of the smallest autosome causing a minimal
reduction in the chromosomal dose. Most of the cancer-
associated chromosomes examined in this study were
found to belong to the gene-poor chromosomes and to
Figure 3 Relationships between the tumor size and tumor progression (A) and recurrence (B) in gastric cancers that were classified
into the four microsatellite genotypes. Each genotype group is divided according to the depth of invasion (T1-2, △; T3-4, ▲), nodal
involvement (N0, ○; N1-3, ●) (A), and recurrence pattern (hematogenous, ▲; lymph node, ■; peritoneal, ●; no recurrence, ○) (B). The details of
genotype classification are described in the material and methods section. The vertical dotted lines indicate the cutoff tumor diameter.
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Page 9 of 14contain fewer stomach-specific genes that were highly
expressed (Table 2). This indicates that the LOH events
tend to target the chromosomes with a low dose of genes
and transcription. Chromosome 17, which contained a
relatively high density of genes and the P53 gene, was
commonly lost in the intestinal- and mixed-type gastric
cancers with a high-level LOH. Meanwhile, chromosome
13, which contained a low density of genes and the RB1
gene, was most frequently lost in the early-onset diffuse-
type cancers with a baseline-level LOH (Table 2) [3].
Therefore, the adverse effect of LOH was found to be
more tolerated in intestinal-type cancers than in diffuse-
type cancers.
The pluripotent mesenchymal stem cells have a high
number of active CpG-island genes dispersed on the
entire chromosomes, whereas lineage-committed
somatic cells establish a high expression of several tis-
sue-specific genes localized on some chromosomes [21].
Given that newly fixed stem cells in young-aged indivi-
duals tend to preserve the mesenchymal cell traits, the
LOH event in young-aged gastric cancer patients can
exert a severe adverse effect by affecting numerous
active genes. This explains the reason why the baseline-
level LOH cases are frequent in diffuse-type gastric can-
cers in young-aged patients [3,4,7]. The LOH event in
old-aged patients may exert a mild adverse effect at a
late adaptation stage of newly fixed stem cells that
establish a high expression of several stomach-specific
genes and the down-regulation of housekeeping genes.
This provides a plausible explanation for the reason why
the high-level LOH cases are related with intestinal-type
gastric cancers common in the old-aged patients.
A comparative analysis of stomach, colon, head, neck
and thyroid cancers has described an association
between the level of LOH and the expression of tissue-
specific genes lacking CpG-islands [11]. The LOH
events are more frequent in gastric cancers along with a
higher expression of stomach-specific genes lacking
CpG-islands in the gastric normal mucosa, when com-
pared with other tissue types. This indicates a mild
adverse effect of LOH events on somatic tissues that
sustain a high expression of tissue-specific genes, which
allow a high-level of LOH. In this regard, the occurrence
of a high-level of LOH as well as distant metastasis may
rely on the tissue type of the cancer’s origin. Similarly, a
previous study [24] has described that the normal cell of
origin is a strong determinant of metastatic spread,
because distinct tissue types show distinct metastatic
tendencies.
In addition to the cell-adverse effect of LOH, dose-
compensatory demethylation provides a plausible expla-
nation for a tissue-type-dependent metastasis tendency.
In high-level LOH gastric cancers, the extensively
demethylated CpG-island genes can protect dissemi-
nated gastric cancer cells from the overmethylation of
the CpG-island genes that induce non-dividing terminal
differentiation in an unfamiliar tissue environment
(Figure 5). A high frequency of the high-level LOH
cases in the intestinal and mixed type of gastric cancers
implicates a dedifferentiation effect on the intestinal dif-
ferentiation (Figure 2). Meanwhile, in the baseline- and
low-level LOH gastric cancers that show a few cases of
disease relapse with distant metastasis, the demethyla-
tion of CpG-island genes appears to be insufficient to
protect cancer cells from the terminal differentiation
induced with the overmethylation of the CpG-island
genes. Therefore, it is likely that a high-level LOH
resulting from a mild adverse effect of LOH in the
stomach tissue environment drives the growth of a
Figure 4 The Kaplan-Meier survival curves of 41 stage II gastric
cancer cases (A) and 52 stage III gastric cancer cases (B). The
patients with stage II (A) or stage III (B) tumor were stratified
according to the low-risk (MSI and low-level LOH) and high-risk
(high-level LOH and the diffuse-type specific baseline-level LOH)
genotypes. The details of genotype classification are described in
the material and methods section. Log-rank tests were performed
to statistically analyze the differences in patient survival.
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Page 10 of 14Table 4 Multivariate analysis of 145 patients with gastric cancer for determining the significant prognostic factors
Category Hazard ratio 95% CI P value
Model 1 (stage II and III); Genotype variables
High- vs. low-risk genotype 22.077 6.57 - 74.18 <0.0001
Stage II vs. III 3.316 2.03 - 5.42 <0.0001
Vein invasion, no vs. yes 0.440 0.23 - 0848 0.014
Age 1.001 0.98 - 1.03 0.957
Sex 0.852 0.44 - 1.67 0.640
Model 2 (stage II and III); No genotype variables
Stage II vs. III 4.310 2.60 - 7.13 <0.0001
Growth pattern, 0.581 0.38 - 0.90 0.014
Sex 2.079 1.02 - 4.24 0.044
Age 0.989 0.97 - 1.02 0.370
Model 3 (stage II); Genotype variables
High- vs. low-risk genotype 15.42 1.71 - 139.5 0.015
Model 4 (stage II); No genotype variables
Tumor size 0.050 0.01 - 0.65 0.022
Histological type 0.167 0.04 - 0.79 0.024
Model 5 (stage III); Genotype variables
High- vs. low-risk genotype 19.69 4.38 - 88.53 <0.0001
Tumor size 1.22 1.02 - 1.46 0.028
Model 6 (stage III); No genotype variables
Vein invasion, no vs. yes 0.30 0.13 - 0.70 0.006
Hazard ratios were estimated in a multivariate analysis using a stepwise procedure. A variable in the model was entered when it was a significant independent
factor (P < 0.05). Hazard ratios less than 1.00 represent a decreased risk of death, whereas hazard ratios greater than 1.00 represent an increased risk of death.
CI, confidence interval.
Figure 5 Schematic diagram of the LOH-related genetic and epigenetic alterations that underlie gastric carcinogenesis. The general
paradigm is that the LOH events exert an adverse effect on cell proliferation and they induce a dose-compensatory response in addition to a
key function of the second hit that targets cancer-associated genes. Newly fixed stem cells are increasingly resistant to the adverse effect of LOH
events during long-term adaptation to the gastric mucosa, since stem cells establish the high expression of stomach-specific genes that is
restricted to some chromosomes. A baseline-level LOH is common in the diffuse-type cancers of young-aged patients at the initial stage of the
adapting stem cells. A high-level LOH has a minimal adverse effect on stem cells at a late adaptation stage in old gastric cancer patients who
harbor a few highly expressed genes on cancer-associated chromosomes. The dose-compensatory demethylation can lead to the interruption of
terminal differentiation and to the persistent expansion of migratory stem cells. The extensive high-dose demethylation leads to the persistent
expansion of lineage-committed migratory cells even in distant foreign tissue-environments.
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Page 11 of 14micrometastasis into a macroscopic metastasis via high-
dose-compensatory demethylation.
The diffuse-type gastric cancers showed a bimodal dis-
tribution for the number of chromosomal losses in con-
sistent with a previous study [3]. In a bimodal
distribution, there were one and four chromosomal
losses that occur frequently. The high-level LOH
induced demethylation might lead to the dedifferentia-
tion of gastric cancer cells that were initially well-
differentiated. Meanwhile, the baseline-level LOH and
low-level LOH cases having a few LOH events are likely
to preserve the differentiation state formed in cancer
progenitor cells. This implies that the histologic type of
a given gastric cancer is variously determined according
to the adaptive differentiation of cancer progenitor cells
as well as the cell-adverse effect of LOH. In the base-
line- and low-level LOH gastric cancers that showed a
few cases of disease relapse with distant metastasis, the
demethylation of CpG-island genes appears to be insuf-
ficient to protect cancer cells from the terminal differ-
entiation induced with the overmethylation of the
CpG-island genes.
The MSI-positive cases were oldest among the four
genotype groups; baseline-, low-, and high-level of LOH
and MSI. Although the gastric cancer patients with low-
level and high-level LOH were older than the baseline-
level LOH cases that were youngest among the four
genotype groups, both the low-level and high-level LOH
cases were younger than the MSI-positive cancer
patients. The result of this study agrees with the pre-
vious studies reporting that the MSI-positive cases were
common in late-onset gastric cancers when compared
with the LOH-positive cases [7,25]. The gastric cancer
with MSI genotype has been known to undergo the
hypermethylation of multiple CpG-island genes invol-
ving the mismatch repair gene, which is associated with
the aging process [12,13,26]. Because the LOH-positive
cases may be influenced by the adverse effect of LOH
on the cancer progenitor cells, the onset age of gastric
cancers is associated distinctly with the LOH and MSI
events.
Comparison of the LOH and DNA-copy-number ana-
lyses has shown that the level of LOH is underestimated
with DNA-copy-number analysis due to the coincidence
of chromosomal losses and gains that involve the same
genomic position [27]. The complicated chromosomal
changes and intra-tumoral heterogeneity have raised a
difficult question about which genetic alteration plays a
main role in cancer initiation and progression. Multifo-
cal microsatellite analyses of the heterogeneous tissue
sites of gastric cancers [3,7,13], sarcomatoid carcinoma
[28] and glandular-neuroendocrine carcinoma [29] have
demonstrated that the distinct cell components always
harbor the same LOH involving the same allele on the
cancer-associated chromosomes. These results suggest
that the primary chromosomal loss and secondary chro-
mosomal gain direct the subclonal expansion of hetero-
geneous cancer cells and that chromosomal losses are
not exactly compensated with chromosomal gains in
view of a dosage compensation.
Dose-compensatory demethylation in response to the
LOH event may up-regulate the CpG-island genes con-
taining CpG islands as well as down-regulate the sto-
mach-specific genes lacking CpG islands. This is
because the housekeeping genes and the tissue-specific
genes share the limited amount of nuclear proteins in a
nuclear space and there is an inverse correlation
between the expression of the two gene groups [21].
However, it is methodologically difficult to define the
accurate expression of the house-keeping genes since
most of the up-regulated housekeeping genes are weakly
active [11,30]. The methylation status of individual
genes is too heterogeneous in heterogeneous tumor sites
to be accurately estimated with small pieces of biopsy
tissue [13]. In this regard, microsatellite analysis is the
method of choice for making the pretreatment genetic
diagnosis of gastric cancer.
The pyrosequencing analysis of single nucleotide poly-
morphism (SNP) is useful to detect LOH [31], but it is
not suitable for MSI detection. Highly repetitive micro-
satellite sequences are useful to analyze the LOH as well
as MSI. The radioisotope-labeling PCR protocol used in
this study is an advantageous method to obtain the spe-
cific PCR bands from a small amount of biopsy tissues
under a stringent condition of minimal PCR cycles. The
genetic instability of cancer that leads to intratumoral
heterogeneity is a difficult problem to be solved for
making an accurate pretreatment genetic diagnosis with
using a small piece of biopsy tissue. A series of radioiso-
tope-labeled microsatellite analyses of gastric cancers
have reported that the level of LOH and MSI are closely
related with the clinicopathologic characteristics and
survival rate of the gastric cancers [3,4,7]. Other non-
radioisotope methods are often problematic for analyz-
ing microsatellite sequences due to a high number of
PCR cycles and the simple nucleotide sequences that
limit designing specific PCR primers.
Conclusions
Although the surgical pathology has been used as the
gold standard, it remains difficult to identify, before sur-
gical resection, the gastric cancer patients who will have
relapsed disease [32]. This study illustrated two distinct
high-risk genotypes, high-level and baseline-level LOH.
The high-level LOH cases recurred through the hemato-
genous route after R0 resection of pathologically non-
metastatic tumors. The baseline-level LOH cases with
early-onset and diffuse-type cancers recurred in the
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Page 12 of 14peritoneal cavity rather than in the distant organs. The
LOH events combined with a cell-adverse effect and a
dose compensatory response in addition to tumor sup-
pressor gene inactivation may activate the stem-cell
intrinsic program and this may determine the due clini-
cal course of gastric cancers before tumor cells appear
as a tumor mass in situ.
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